giichinese.com logo
giichinese.com logo
日商環球訊息有限公司


垂直整合市場
- Japanese Korean English
Report
[英文調查報告書]

中外製藥:製藥企業分析報告

Chugai: Pipeline, Products, Performance, Potential

商品編碼 : 42291
出版日期 : 2008/03

Price

-
此出版品為英文撰寫

Abstract

As a member of the Roche Group, Chugai has rights to develop and market all pharmaceutical products which the Roche Group decides to commercialise in Japan. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.

Chugai Pharmaceutical's net sales for 2005 were ¥327,200 million, an 11% increase over 2004. Operating income was up by 54% to ¥79,200 million, due to product sales increases and cost saving measures. Net income rose by 57% to ¥53,600 million, due mostly to extraordinary gains from milestone income from Roche related to co-development of Actemra.

Chugai's reliance on the tough Japanese market has led to a range of initiatives for overseas expansion. It is building an independent development and sales infrastructure in Europe and other overseas markets and formulating a marketing strategy that will establish an autonomous marketing network in the US.

R&D Pipeline Overview

  • Antevas has been filed for the treatment of disorders caused by acute cerebrovascular diseases.
  • ED-71 is an oral vitamin D3 derivative in Phase III trials for the treatment of osteoporosis.
  • VAL has completed Phase II trials in Japan for use in post-hepatectomy/liver transplantation.
  • CHS13340, a nasal spray formulation of recombinant human parathyroid hormone, has been licensed from Daiichi Suntory Pharma, and is in Phase II trials for osteoporosis.
  • Tarceva is expected to be filed for non-small cell lung cancer in the first half of 2006.

Major Products Forecast to 2010

  • Rythmodan (Cardiovascular)
  • Alfurol (Bone Metabolism)
  • Epogin (Haematological)
  • Neutrogin/Granocyte (Haematological)
  • Sigmart/Ikorel (Cardiovascular)
  • Rituxan (Anticancer)
  • Tamiflu (Antiviral)

Table of Contents

Latest Results

EXECUTIVE SUMMARY

  • Introduction
  • Financial Performance 2005
    • Sales and Marketing Position
    • Income
      • Sales, Costs and Operating Income
    • Expenditure
      • Capital Expenditure
      • R&D Expenditure
    • Divisional Performance
    • Geographic Performance
      • Sales by Geographic Area
      • Sales by Geographic Area, 2005
  • Company Strategy
    • Merger with Nippon Roche
    • Sunrise 2010
    • Mergers, Acquisitions and Divestitures
    • Key Agreements
    • Production
    • Employees
  • Product/R&D Overview
    • Key Products
      • Recent Product Launches
      • Recent Product Approvals
    • R&D Strategy
      • Key R&D Projects
    • Sales Forecast
      • Sales of Major Products (2000A-2010E)
    • R&D Pipeline Overview
      • Discontinued R&D Projects
  • Conclusions

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

  • Major Products, Therapeutic Areas and Sales
  • Breakdown of Sales by Therapeutic Area, 2005
  • Top Selling Products, 2006
  • R&D Pipeline - Japan
  • R&D Pipeline - Overseas
  • Haematological - Products
    • Major Launched Products
    • Epogin
      • Sales
      • Indications
      • Further Development
      • Patents
      • Competitor Products
      • Sales Forecast
    • Epogin Sales (2000A-2010E)
    • Neutrogin/Granocyte
      • Sales
      • Key Markets/Indications
      • Sales Forecast
    • Neutrogin Sales (2000A-2010E)
  • Haematology - R&D
    • R&D Pipeline - Japan
    • R744
  • Haematology - Summary
    • Growth Potential
    • Limiting Factors
  • Anticancer, Chemotherapeutic - Products
    • Major Launched Products
    • Femara
    • Furtulon
    • Herceptin
      • Sales
      • Key Markets/Indications
      • Further Development
    • Rituxan
      • Sales
      • Indications
      • Safety Issues
      • Sales Forecast
    • Rituxan Sales (2000A-2010E)
    • Tamiflu
      • Sales
      • Indications
      • Competitor Products
      • Sales Forecast
    • Tamiflu Sales (2000A-2010E)
    • Xeloda
      • Sales
      • Indications
      • Further Development
  • Anticancer, Chemotherapeutic - R&D
    • R&D Pipeline - Japan
    • Avastin
    • Omnitarg
    • Tarceva
  • Anticancer, Chemotherapeutic - Summary
    • Growth Potential
    • Limiting Factors
  • Cardiovascular, Respiratory - Products
    • Major Launched Products
    • Inhibace
    • Renagel
      • Sales
      • Markets/Indications
    • Rythmodan
      • Sales
      • Sales Forecast
    • Rythmodan Sales (2000A-2010E)
    • Sigmart/Ikorel
      • Sales
      • Licensees
      • Indications
      • Sales Forecast
    • Sigmart Sales (2000A-2010E)
  • Cardiovascular, Respiratory - R&D
    • R&D Pipeline - Japan
    • Antevas (AVS)
  • Cardiovascular, Respiratory - Summary
  • Hormones, Vitamins, Tonic - Products
    • Major Launched Products
    • Alfarol
      • Sales
      • Sales Forecast
    • Alfarol Sales (2000A-2010E)
    • Oxarol/OCT
      • Sales
      • Further Development
  • Hormones, Vitamins, Tonic - Summary
  • Metabolic - R&D
    • Japanese R&D Pipeline
    • CHS13340
    • ED-71
    • Ibandronic Acid (R484)
    • R483
  • Metabolic - Summary
  • Gastrointestinal - Products
    • Major Launched Products
    • Kytril
      • Sales
    • Ulcerlmin
  • Gastrointestinal - R&D
    • R&D Pipeline - Japan
    • R&D Pipeline - Overseas
    • Mitemcinal Fumarate (GM-611)
    • VAL
  • Gastrointestinal - Summary
  • Central Nervous System - Products
    • Amoban
  • Central Nervous System - Summary
  • Antibiotic - Products
    • Major Launched Products
    • Rocephin
      • Sales
      • Indications
  • Other - Products
    • Major Launched Products
    • Actemra 200
      • Key Markets/Indications
      • Further Development
      • Clinical Trial Results
    • Pegasys
      • Sales
      • Indications
      • Further Development
  • Other - R&D
    • R&D Pipeline - Japan
    • R&D Pipeline - Overseas

APPENDIX 1- FINANCIAL PERFORMANCE

  • Full Year Results 2005
    • Sales, Costs and Operating Income
    • Profitability and Research Ratios
    • R&D Expenditure and Capital Expenditure
    • Current Assets, Liabilities and Ratio
    • Assets, Cash and Liquidity
    • Employees and Productivity

APPENDIX 3 - KEY AGREEMENTS

  • Abgenix Inc
    • 3rd February 2003
  • Cerus Corporation
    • 22nd December 2004
  • Cambrex Bio Science Walkersville
    • 21st February 2006
  • Eli Lilly
    • 13th December 1995
  • Genzyme General
    • December 1994
  • Roche
    • 5th April 2002
    • 3rd October 2002
    • 25th February 2003
    • 15th December 2003
    • 27th April 2004
  • Xencor Inc
    • 10th January 2005

APPENDIX 4 - INFRASTRUCTURE

  • Research and Development Facilities
  • Manufacturing Facilities

APPENDIX 5 - KEY PHARMACEUTICAL

  • SUBSIDIARIES/JOINT VENTURES
  • Subsidiaries
  • Joint Ventures

APPENDIX 6 - PRODUCT INDEX

-
此出版品為英文撰寫

Top

[英文調查報告書]
中外製藥:製藥企業分析報告
Chugai: Pipeline, Products, Performance, Potential

出版商 : Espicom Business Intelligence Espicom Business Intelligence
代理商 : Global Information, Inc. Global Information, Inc.

US $ 1,220 (Hard Copy)
US $ 1,220 (PDF by E-mail (Single User License))
US $ 1,220 (Web Access (Single User))
商品編碼 : 42291

本頁所標示之售價為不含購買者所在地消費稅之未稅價格,相關消費稅金將另行加至交易金額中